Medical Devices Startups

Optobio makes the Xpress ELISA, a 48-channel automated ELISA instrument with an integrated chemiluminescence detector that delivers results in under an hour using small sample volumes. The device supports multiplexed or single-plexed assays with 18 validated tests for laboratory immunoassay applications.

1 investor

Opus Medical provides personalized case management services for injured workers, matching clinical oversight to the severity of each injury. It supports workers and employers through the recovery process using clinical coordination and evidence-based practices, primarily in the workers' compensation context.

1 investor

OpZira develops wearable and diagnostic testing systems for the detection and monitoring of retinal and visual pathway diseases. The company serves eye care professionals and healthcare providers working with patients at risk for or diagnosed with ocular conditions.

1 investor

OraLiva develops an AI-powered, non-invasive oral cancer test designed to detect cancer early during routine dental visits, using single-cell analysis and microfluidic technologies. The company is advancing a point-of-care diagnostic device for dental networks, building on its current lab-developed platform.

1 investor

ORamaVR develops a platform for high-fidelity medical simulation training using extended reality technology, serving device companies, simulation centers, and hospitals globally. The company addresses the challenge of scaling medical education through spatial computing and computer graphics innovations.

1 investor

Orchestra BioMed develops medical device products and uses a partnership-based model, collaborating with medical device companies to commercialize them globally. It operates in the medical device and biomedical industry.

1 investor

Orchid Hospital operates two healthcare facilities in Phnom Penh, Cambodia, providing specialized obstetrics, gynecology, pediatrics, maternity care, and general medical services. The hospital combines modern facilities with clinical expertise to serve patients across multiple disciplines including ENT and multi-specialty treatments.

1 investor

Orchid provides contract manufacturing services for orthopedic medical devices to original equipment manufacturers and emerging companies in the medical device industry.

1 investor

Orchidia is a pharmaceutical company that completed a third investment round in 2026 with strategic international investors including SPE Capital, Proparco, EBRD, and BIO.

1 investor

Organ Recovery Systems develops organ preservation products and services, including machine perfusion technology for donor kidneys, for transplant programs and transplant professionals. The company supports over 400 transplant programs across 49 countries and also provides clinical and technical support services.

1 investor

Organo-ID develops iPSC-derived organoid systems, including 3D hepatocyte models, to test drugs in better-modeled biological systems for predictive diagnostics and personalized therapies. The company serves drug development and treatment applications in oncology and rare disease, operating from Turkey with a global focus.

1 investor

Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

1 investor

Orienda International Hospital is one of Cambodia's larger hospitals providing medical care with a focus on patient satisfaction and modern facilities. The hospital operates with international standards and a team of medical specialists across diverse healthcare needs.

1 investor

Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.

1 investor

Origin Endoscopy has developed a multipurpose hydrogel designed for rapid bio-adhesion and submucosal injection applications in endoscopy. The technology targets surgical and medical procedure workflows that require biocompatible materials.

1 investor

Origin Medical develops a real-time AI assistant for prenatal ultrasound examinations that aims to shorten exam times, standardize workflows, and reduce errors. It serves sonographers, reading physicians, health systems, and private practices to improve the quality and consistency of prenatal scans and patient care.

1 investor

Origin Sciences applies a hologenomic approach integrating host genetics, epigenetics, and microbiome analysis into a single diagnostic framework for deeper health assessment. The company works with leading institutions and technology providers to develop and scale advanced diagnostic assays for clinical and research applications.

1 investor

Origyn Medical develops minimally invasive gynecological medical devices, including hysteroscopy instruments, cervical health products, women's rehabilitation devices, and gynecological diagnostic tools such as a single-use electronic endoscope. The company serves clinicians and hospitals in the women's health field, with operations in Hangzhou and Hunan, China.

1 investor

Pareon Biosystems has developed a multiplex biomarker quantification method that produces absolute measurements with built-in correction for non-specific binding. The approach uses low concentrations of common reagents and standard lab equipment such as PCR, targeting personalized/precision medicine applications in research and clinical settings, including resource-limited environments.

1 investor

Orio Therapeutics develops protein-based therapeutics using a technology that modifies therapeutic proteins with a built-in delivery system to control their localization at the injection site, improving efficacy and reducing dosage in regenerative medicine. Its first application is a molecule to protect cardiac muscle following a heart attack (myocardial infarction) by reducing fibrosis and cellular death.

1 investor

Orogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.

1 investor

Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent. The company has successfully brought trientine tetrahydrochloride (Cuprior®/Cuvrior®) to market for Wilson disease treatment across 30+ countries.

1 investor

Ortho BioMed combines expertise in medicine, engineering, and data science to develop medical technology solutions that improve patient outcomes.

1 investor

OrthoPreserve develops a minimally invasive meniscus implant for orthopedic care, designed to address unmet clinical needs in knee surgery. The company is co-founded by orthopedic clinicians and engineers with expertise across R&D, manufacturing, regulatory compliance, and surgical practice.

1 investor